Table 3. Overview of the quantity and quality of final UCB-NK products generated from enriched CD34+ cells using static bags and single use bioreactors.
Donor | CD34+ cells (x106) | fold expansion | CD56+ cells (%) | CD56+ cells (x109) | |
static bag | 7 | 1.7 | 1,770 | 63 | 1.9 |
8 | 1.4 | 759 | 80 | 0.9 | |
9 | 1.3 | 1,291 | 70 | 1.2 | |
bioreactor | 10 | 0.9 | 2,549 | 95 | 2.2 |
13 | 1.5 | 1,764 | 90 | 2.4 | |
15 | 1.5 | 2,657 | 92 | 3.7 | |
16 | 1.2 | 1,435 | 92 | 1.6 |
The table summarizes the generation of UCB-NK cell therapy products generated in static bags (Donor 7, 8 and 9) or bioreactors cultures (Donor 10, 13, 15 and 16).